Profound Medical Welcomes New Chief Commercial Officer
Profound Medical Corp., a forward-thinking medical device company, has made a noteworthy addition to its executive team with the appointment of Tom Tamberrino as Chief Commercial Officer. This development signals a strategic move as the company gears up for exciting advancements in the treatment landscape of prostate disease.
Strategic Leadership Changes
In a recent announcement, Profound cited the decision to enable Abbey Goodman, the previous Chief Commercial Officer, to drive strategic partnerships, thereby allowing Tom to step into the crucial role focused on commercial leadership. Under the guidance of CEO and Chairman Arun Menawat, Profound's enhanced team structure aims to leverage existing relationships and establish new ones within the healthcare sector.
Tom Tamberrino's Impressive Background
Tom Tamberrino brings a wealth of experience to Profound, having a robust history in sales and marketing within the healthcare industry. His most recent position was Vice President of Sales and Marketing at NOVADAQ Technologies, where he contributed to significant growth before the company was acquired by Stryker. His expertise in building sales organizations will be vital as Profound prepares for the rollout of the permanent CPT Category 1 codes, set to enhance patient access to innovative solutions in prostate treatment.
Preparing for Market Transformations
The upcoming implementation of new payment codes represents a pivotal moment for Profound Medical and its TULSA-PRO system, an advanced medical device designed for the treatment of prostate conditions. Tom's role will be critical in articulating the core benefits of TULSA to both patients and healthcare providers, thereby unlocking the device's potential in various clinical settings.
A Vision for Comprehensive Treatment
During his tenure at NOVADAQ, Mr. Tamberrino played an essential role in establishing the company as a leader in surgical imaging technologies. By transitioning to Profound, he aims to replicate this success by creating awareness around TULSA, which utilizes real-time MRI guidance to deliver an incision-free treatment option for prostate cancer and related ailments. With reimbursement structures coming into place, the opportunity for TULSA to thrive has never been greater.
Collaboration and Growth
The transition of Abbey Goodman into strategic partnerships is equally exciting for Profound. By leveraging her extensive experience and networking skills, Profound intends to cultivate stronger ties with other medical technology firms, working towards a cohesive diagnostic and interventional MRI solution. This collaboration is aimed at improving the accuracy of diagnoses and the effectiveness of treatments through integrated healthcare approaches.
The Impact of TULSA Technology
The TULSA procedure is at the forefront of non-invasive treatments, presenting a unique opportunity for patients with urinary continence and sexual function considerations. As the team at Profound focuses on maximizing the reach of TULSA, they envision it becoming a mainstream option for a broad range of prostate conditions. Additionally, Profound also introduces the Sonalleve platform, which marks significant strides in treating uterine fibroids and pain management associated with bone metastases.
Closing Insights
In welcoming Tom to the executive team, Dr. Menawat expressed confidence in his ability to lead Profound through a transformative period. As the company prepares for the future, its focus lies squarely on driving innovations that enhance patient care and deliver meaningful outcomes. The collective efforts from both new and existing leaders are set to bear fruit in a dynamic healthcare marketplace.
Frequently Asked Questions
What position has Tom Tamberrino been appointed to at Profound Medical?
Tom Tamberrino has been appointed as the new Chief Commercial Officer of Profound Medical Corp.
What does TULSA-PRO technology do?
TULSA-PRO technology offers a non-invasive treatment option for prostate conditions, utilizing real-time MRI guidance.
How will the new CPT codes impact Profound Medical?
The new CPT Category 1 codes for TULSA are expected to improve patient access and support the commercial growth of the technology.
Who will lead the strategic partnerships at Profound Medical?
Abbey Goodman will transition into the role of leading strategic partnerships within Profound Medical.
What other technology is Profound Medical commercializing?
In addition to TULSA-PRO, Profound Medical is also commercializing Sonalleve, targeting uterine fibroids and palliative pain treatment.
